PETAH TIKVA, Israel & BOCA RATON, Fla. — Biobeat Technologies, the developer of the first FDA-cleared cuff-less 24-hour ambulatory blood pressure monitoring (ABPM) system, has closed a $50 million Series B equity financing round. The investment, led by Ally Bridge Group, OrbiMed Advisors, and Elevage Medical, signals a major shift in how the medical community approaches the diagnosis and management of hypertension for over 100 million patients in the United States.
For decades, the standard method for 24-hour monitoring has relied on inflatable arm cuffs that trigger at regular intervals, often waking patients during the night or interrupting daily activities. These disruptive inflation cycles have historically led to low patient compliance and logistical challenges for clinical staff tasked with collecting and cleaning the hardware. Biobeat’s solution replaces this bulky equipment with a discreet, disposable, patch-worn sensor. This allows patients to maintain their normal routines while high-quality data is automatically synced to electronic medical records in seconds, eliminating the need for manual data entry.
The company plans to use the new capital to rapidly expand its commercial presence in the U.S. market. Raymond W. Cohen, Executive Chairman of Biobeat, compared the potential impact of the device to the revolution seen in ambulatory ECG monitoring, which saw a massive spike in clinical use once patch-worn technology replaced traditional wired monitors. As part of the funding agreement, the company has added Steven Plachtyna of Ally Bridge, Dina Chaya of OrbiMed, and Evan Melrose of Elevage to its Board of Directors to guide this next phase of growth.
CEO Arik Ben Ishay emphasized that the goal is to establish Biobeat’s technology as the true standard of care. By providing a more comfortable, clinically validated alternative to the traditional cuff, the company aims to help physicians more accurately diagnose hypertension and titrate medications for a massive and growing patient population.
